Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023473 (chronic myeloid leukemia)
 18,916 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

An uncommon, but lethal, toxic side effect of busulfan (Myleran) therapy for chronic myelogenous leukemia is pulmonary fibrosis. A 16-month-old male infant treated for 11 months with busulfan for chronic myelogenous leukemia is, we believe, the first case of "busulfan lung" in the pediatric age group to be reported. Progressive roentgenographic changes in the lung of a diffuse intra-alveolar and interstitial pattern were noted. The patient died after a four-day episode of cough, fever, and progressive dyspnea. At autopsy, no evidence of infection or leukemic infiltrates were seen in the lungs. Characteristic histologic findings as a result of busulfan therapy were observed in the lung and pancreas.
 ...
PMID:Busulfan lung. 26 39

A patient with chronic granulocytic leukemia was treated with Busulfan for the three last months of pregnancy. The infant appeared normal except for an atypical tapetoretinal degeneration. We studied the other cases in the literature. All pregnancies produced an apparently normal infant although three infants were small. The case of Diamond had microphthalmia. We conclude that Busulfan is perhaps toxic to fetal retina.
 ...
PMID:[Degenerative retinal conditions after treatment with Busulfan during pregnancy (author's transl)]. 26 48

In four patients with chronic myelocytic leukemia, a solitary rise in serum alkaline phosphatase (S-ALP) was noted 2--12 months prior to death. All patients had received busulphan (Myleran) therapy for longer than 12 months (total dosage 1.0--2.4 g). It is suggested that the increase in S-alp was due to a cholestatic liver damage, possible secondary to the busulphan treatment.
 ...
PMID:Increase in serum alkaline phosphatase (S-ALP) in chronic myelocytic leukemia--sign of drug-induced cholestasis? 27 22

Autopsy findings from two patients who have been treated for several years with Busulfan because of chronic myelogenous leukemia are reported. Beside a pulmonary fibrosis epithelial dysplasias in the respiratory tract, the liver and kidney were detected. Furthermore, in one case beside a proliferation of reticulate cells in the spleen a distinct plasmocytosis of the bone marrow and a so-called "wasting syndrome" were found. The pathogenesis of these changes is still unkown; it may be that immunological processes play a role.
 ...
PMID:[Morphological findings after Busulfan long term therapy (author's transl)]. 82 30

Chronic granulocytic leukemia developed in a 59-year-old woman who had previously received a total of 21 mCi -32P for polycythemia vera. She was treated with Myleran (busulphan) for her chronic granulocytic leukemia. Cytogenic studied revealed deletion of chromosomes No. 8 and 12, and translocation between 1 and 8. The patient also developed a severe antoimmune hemolytic anemia, for which she received prednisone treatment. She died with a perforated stomach ulcer.
 ...
PMID:Polycythemia vera treated with -32p and myleran: development of chronic granulocytic leukemia with chromosomal abnormalities in one patient. 105 76

Sixteen Zambian Africans with chronic myeloid leukaemia are described. Clinical and haematological features were unremarkable except for the relative extreme youth of three patients (aged 18 years or less) and one patient with the aleukaemic form in whom the diagnosis was proved by marrow examination. Thirteen patients were treated with busulphan (Myleran), of whom 12 showed varying degrees of responsiveness, and one was completely resistant both to busulphan and cyclophosphamide. One patient became pregnant while receiving busulphan and another showed depression of spermatogenesis when investigated four years after start of treatment. The poor responsiveness of some Africans to busulphan is briefly speculated upon.
 ...
PMID:Chronic myeloid leukaemia in Zambians. 105 59

The Western Cancer Study Group (WCSG) retrospectively reviewed chronic granulocytic leukemia (CGL) diagnosed during 1960 to 1974 from 22 institutions. In 100 cases, patients had positive findings for the Philadelphia chromosome (Ph'+). In 426 cases karyotyping was not done (Ph'?). Ten patients had no Ph' chromosome (Ph'-). The ten Ph'- patients ranged in age from 8 to 85 years and in survival from 1 to more than 125 months. Their small number and heterogeneity precluded statistical analysis, but this notable heterogeneity of the Ph'- group may well be typical. Busulfan prolonged survival in the Ph'+ and Ph'? patients. Females and younger patients tolerated their disease better than males and older patients. Survival studies without reference to the Ph' status, treatment, age at diagnosis, and sex are probably not valid.
 ...
PMID:Chronic granulocytic leukemia. Review of 536 cases. 106 70

The results of an investigation on platelet antibodies by thromboagglutination and antiglobulin consumption test (AGCT) in 51 patients with different types of hemoblastoses (acute and chronic leukemias, Hodgkin disease, lymphosarcoma) are reported. Complete and/or incomplete antibodies were found in 50,9% of the cases, with lymphoid forms showing the highest frequency. Although a constant relation between thrombocytopenia and platelet antibodies is by no means demonstrable, four fully descirbed cases clearly show and the onset of autoimmune thrombocytopenia in the course of hemoblastoses. Two chronic myeloid leukemia cases treated with Myleran and one chronic lymphoid leukemia case presented thrombocytopenic purpura and normal number of megakaryocytes. One case of lymphosarcoma presented thrombocytopenia and autoimmune hemolytic anemia with bone marrow aplasia. Steroid therapy had been partially effective only in two cases. The pathogenetic relationship between platelet immunization and hemoblastoses and cytostatic therapy is discussed.
 ...
PMID:[Autoimmune thrombocytopenia in the course of hemoblastosis]. 106 96

Chronic myelocytic leukemia and the myeloproliferative diseases may present as asymptomatic elevations of peripheral blood counts or with relatively nonspecific symptoms. Full diagnostic evaluation is necessary to eliminate the many other causes of blood count elevation. Coincidence of a myeloproliferative disease and pregnancy is unusual. The pregnancy has no adverse effect on the course of the mother's hematologic disease. However, the myeloproliferative diseases, especially if uncontrolled, result in increased fetal prematurity and mortality. Treatment of the pregnant patient should be conservative, and cytotoxic therapy should be avoided until at least after the first trimester whenever possible. Busulfan has been the drug most widely used during pregnancy, and it appears not to cause fetal malformations when used alone.
 ...
PMID:Chronic myelocytic leukemia and the myeloproliferative diseases during the child-bearing years. 106 96

Adrenal function was studied in patients with chronic myeloid leukaemia treated in the past or presently with Busulphan. Adrenocortical function was determined by means of 24-hour profile of 11-hydroxysteroids (11-OHCS) in plasma, and urinary 24-hour 17 hydrocorticosteroids (17-OHCS) and 17-ketosteroids (17-KS). The adrenomedullary function was determined measuring VMA level in 24-hour urine. In most patients normal 24-hour 11-OHCS profiles and 24-levels of 17-OHCS, 17-KS and VMA. Only in some cases these levels were raised. This rise was observed more frequently in patients with blastic crisis of myeloid leukaemia which may indicate that the adrenal reserve was maintained in these patients. The investigations failed to show that the disease itself or Busulphan treatment impaired adrenal function. The possibility of a direct effect of Busulphan on melanin metabolism in the organism is discussed.
 ...
PMID:[Adrenal function in chronic myeloid leukemia]. 106 55


1 2 3 4 5 6 7 8 Next >>